Your browser doesn't support javascript.
loading
Cannabis legalisation: should doctors be concerned?
Kanniah, Guna; Kumar, Shailesh.
Afiliação
  • Kanniah G; M.Clin.Pharm.,PG Cert.Psychopharmacotherapy, Senior Clinical Pharmacist, Mental Health and Addictions Services, Waikato Hospital, PO Box 3200 Hamilton, New Zealand.
  • Kumar S; FRANZCP, MRCPsych, MPhil (London), DPM, Dip CBT, MD (Auck), Consultant Psychiatrist, Midland Regional Forensic Psychiatric Service, Honorary Clinical Associate Professor, University of Auckland.
N Z Med J ; 134(1537): 84-90, 2021 06 25.
Article em En | MEDLINE | ID: mdl-34239164
ABSTRACT
A referendum on the Cannabis Legalisation and Control Bill was held in New Zealand. The Bill was meant to oversee government control over the production, supply and use of cannabis and reduce cannabis-related harm. Public health control was proposed over cannabis market by imposing licenses and cultivation, the quality and strength of marketed cannabis, and sale restrictions. Under this Bill, cannabis was only meant to be available to adults aged over 20 years through licenced stores. The potency of cannabis was to be limited. Cannabis use and was going to be permitted in private homes and specifically licensed premises. The Electoral Commission announced on 6 November 2020 that 50.7% of voters opposed the Bill and 48.4% supported it. Despite the outcome of the referendum, legalisation of cannabis may remain a live issue for many people, and doctors need to have an informed view about the impact of legalisation on mental health conditions. Experience from other countries shows that access to and potency of cannabis increased with legalisation. Despite the intent to prevent harm, cannabis legislation has been associated with adverse effects on mental health, emergency hospital presentations and crime. Public health strategies, including educating public about harm associated with cannabis, surveillance of potency and labelling, increasing minimal age for legal recreational cannabis use and bolstering treatment capacity for problematic cannabis use, including those with psychiatric disorders, should be funded by revenue generated from cannabis legislation.
Assuntos
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Fumar Maconha / Atitude do Pessoal de Saúde / Saúde Mental / Uso da Maconha / Legislação de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: N Z Med J Ano de publicação: 2021 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Fumar Maconha / Atitude do Pessoal de Saúde / Saúde Mental / Uso da Maconha / Legislação de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: N Z Med J Ano de publicação: 2021 Tipo de documento: Article